<DOC>
	<DOCNO>NCT00241553</DOCNO>
	<brief_summary>This study multicentre , double-blind , randomise , placebo-controlled parallel group study consist 4 visit period 6 month . The primary variable ass theefficacy esomeprazole 40 mg orally qd ( E40 ) esomeprazole 20 mg orally qd ( E20 ) versus placebo orally qd 6 month treatment prevention relapse upper GI symptom associate NSAID use , include COX-2 selective NSAIDs , patient receive daily NSAID therapy .</brief_summary>
	<brief_title>Esomeprazole Prevention Upper Gastrointestinal Symptoms Associated With Continuous Use NSAIDs</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Signed informed consent . Completed SHNEN0003 study relief upper GI symptom . Relief define `` last 7 day diary assessment None Minimal , allow 2 day rat Mild 7day period '' . A clinical diagnosis chronic condition ( e.g. , osteoarthritis rheumatoid arthritis ) require continuous daily NSAID treatment least 6 month . Daily NSAID treatment define take prescribed dose least 5 7 day give week include COX2 selective NSAIDs , multiple NSAIDs , highdose NSAIDs . Daily NSAID treatment dose type : Must stable least 9 week prior inclusion Are expect remain stable duration study . Must administer orally . If one type NSAID treatment use , least one type must administer orally . Hp negative Histology perform baseline endoscopy study SHNEN0003 . Discontinuation study SHNEN0003 Pain , discomfort burn upper abdomen precipitate exercise relieve defecation . Pain , discomfort burn upper abdomen associate use NSAIDs , include COX2 selective NSAIDs . Pregnancy lactation . Women childbearing potential must maintain effective contraception study period judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>